Additional Information

Description

Tirzepatide 60mg/3mL (20mg/mL) is a medication used primarily for the management of type 2 diabetes. It is a GLP-1 receptor agonist and GIP receptor agonist, which work together to regulate blood sugar levels by enhancing insulin secretion in response to meals and suppressing glucagon release. 

This formulation is presented in a 3mL vial, with each mL containing 10mg of tirzepatide, resulting in a total of 30mg per vial. It is typically administered via subcutaneous injection once a week, with the dosage tailored based on the patient’s medical needs and response to treatment. The medication should be used in conjunction with a proper diet and exercise plan.

Patients using tirzepatide may experience side effects such as nausea, vomiting, diarrhea, and decreased appetite. Serious but rare side effects can include pancreatitis or allergic reactions. Close monitoring by a healthcare provider is recommended to ensure the medication's efficacy and safety.